Emerging drugs for hepatocellular carcinoma

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Hepatocellular carcinoma is often diagnosed at an advanced stage, when potentially curative surgical or local ablative therapies are not feasible. There is no effective chemotherapy for hepatocellular carcinoma. Recent advances in cancer biology suggest that a limited number of signalling pathways may be responsible for uncontrolled cell proliferation, the major cellular alteration responsible for the cancer phenotype. Novel anticancer agents target these critical pathways, including the receptor tyrosine kinase pathways, the Wnt/β-catenin signalling pathway, the ubiquitin/proteasome degradation pathway, the DNA methylation and histone deacetylation pathways, the PI3 kinase/AKT/mTOR pathway, angiogenic pathways, telomerase and the cell cycle. These agents hold promise for improving the outcome of patients with intermediate and advanced hepatocellular carcinoma. Because of the high prevalence of liver cirrhosis in hepatocellular carcinoma patients, to achieve long-term survival of the majority of patients, targeted anticancer therapies will need to be coupled with strategies aimed at reversing the progression of chronic liver disease.

Original languageEnglish (US)
Pages (from-to)469-487
Number of pages19
JournalExpert Opinion on Emerging Drugs
Volume11
Issue number3
DOIs
StatePublished - Sep 2006

Fingerprint

Hepatocellular Carcinoma
Pharmaceutical Preparations
Catenins
Wnt Signaling Pathway
Critical Pathways
Telomerase
Receptor Protein-Tyrosine Kinases
DNA Methylation
Proteasome Endopeptidase Complex
Ubiquitin
Phosphatidylinositol 3-Kinases
Liver Cirrhosis
Antineoplastic Agents
Histones
Liver Diseases
Neoplasms
Cell Cycle
Chronic Disease
Cell Proliferation
Phenotype

Keywords

  • Cancer signalling pathways
  • Chemotherapy
  • Hepatocellular carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Emerging drugs for hepatocellular carcinoma. / Roberts, Lewis Rowland; Gores, Gregory James.

In: Expert Opinion on Emerging Drugs, Vol. 11, No. 3, 09.2006, p. 469-487.

Research output: Contribution to journalArticle

@article{13693299ddac4c2e83f5863eda5620a1,
title = "Emerging drugs for hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma is often diagnosed at an advanced stage, when potentially curative surgical or local ablative therapies are not feasible. There is no effective chemotherapy for hepatocellular carcinoma. Recent advances in cancer biology suggest that a limited number of signalling pathways may be responsible for uncontrolled cell proliferation, the major cellular alteration responsible for the cancer phenotype. Novel anticancer agents target these critical pathways, including the receptor tyrosine kinase pathways, the Wnt/β-catenin signalling pathway, the ubiquitin/proteasome degradation pathway, the DNA methylation and histone deacetylation pathways, the PI3 kinase/AKT/mTOR pathway, angiogenic pathways, telomerase and the cell cycle. These agents hold promise for improving the outcome of patients with intermediate and advanced hepatocellular carcinoma. Because of the high prevalence of liver cirrhosis in hepatocellular carcinoma patients, to achieve long-term survival of the majority of patients, targeted anticancer therapies will need to be coupled with strategies aimed at reversing the progression of chronic liver disease.",
keywords = "Cancer signalling pathways, Chemotherapy, Hepatocellular carcinoma, Targeted therapy",
author = "Roberts, {Lewis Rowland} and Gores, {Gregory James}",
year = "2006",
month = "9",
doi = "10.1517/14728214.11.3.469",
language = "English (US)",
volume = "11",
pages = "469--487",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Emerging drugs for hepatocellular carcinoma

AU - Roberts, Lewis Rowland

AU - Gores, Gregory James

PY - 2006/9

Y1 - 2006/9

N2 - Hepatocellular carcinoma is often diagnosed at an advanced stage, when potentially curative surgical or local ablative therapies are not feasible. There is no effective chemotherapy for hepatocellular carcinoma. Recent advances in cancer biology suggest that a limited number of signalling pathways may be responsible for uncontrolled cell proliferation, the major cellular alteration responsible for the cancer phenotype. Novel anticancer agents target these critical pathways, including the receptor tyrosine kinase pathways, the Wnt/β-catenin signalling pathway, the ubiquitin/proteasome degradation pathway, the DNA methylation and histone deacetylation pathways, the PI3 kinase/AKT/mTOR pathway, angiogenic pathways, telomerase and the cell cycle. These agents hold promise for improving the outcome of patients with intermediate and advanced hepatocellular carcinoma. Because of the high prevalence of liver cirrhosis in hepatocellular carcinoma patients, to achieve long-term survival of the majority of patients, targeted anticancer therapies will need to be coupled with strategies aimed at reversing the progression of chronic liver disease.

AB - Hepatocellular carcinoma is often diagnosed at an advanced stage, when potentially curative surgical or local ablative therapies are not feasible. There is no effective chemotherapy for hepatocellular carcinoma. Recent advances in cancer biology suggest that a limited number of signalling pathways may be responsible for uncontrolled cell proliferation, the major cellular alteration responsible for the cancer phenotype. Novel anticancer agents target these critical pathways, including the receptor tyrosine kinase pathways, the Wnt/β-catenin signalling pathway, the ubiquitin/proteasome degradation pathway, the DNA methylation and histone deacetylation pathways, the PI3 kinase/AKT/mTOR pathway, angiogenic pathways, telomerase and the cell cycle. These agents hold promise for improving the outcome of patients with intermediate and advanced hepatocellular carcinoma. Because of the high prevalence of liver cirrhosis in hepatocellular carcinoma patients, to achieve long-term survival of the majority of patients, targeted anticancer therapies will need to be coupled with strategies aimed at reversing the progression of chronic liver disease.

KW - Cancer signalling pathways

KW - Chemotherapy

KW - Hepatocellular carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=33748653168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748653168&partnerID=8YFLogxK

U2 - 10.1517/14728214.11.3.469

DO - 10.1517/14728214.11.3.469

M3 - Article

VL - 11

SP - 469

EP - 487

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -